Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Opiant Pharmaceuticals is a pharmaceutical company that develops treatments for drug overdose and addictions leveraging intranasal and injectable delivery technologies. The company, formerly known as Lightlake Therapeutics, was founded in 2009, has a team of addiction experts, and is headquartered in Santa Monica, California.

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations Roger Crystal - President, Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Carl Byrnes - Northland Capital Markets Trevor Allred - Oppenheimer Operator Greetings, and welcome to Opiant Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript

Mind Medicine MindMed

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board.

MindMed Strengthens Board with Appointment of Two New Independent Directors

SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional approximately $2.1 million to support OPNT003, nasal nalmefene, for the treatment of opioid overdose. The increase in funding is primarily directed towards the preparation and filing of a New Drug Application (NDA) for OPNT003 to the U.S. Food and Drug Administration (FDA).

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

SANTA MONICA, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/461,354, with formulation and method of use claims around OPNT003, the Company's investigational treatment for opioid overdose. The allowed patent application, entitled, “Compositions and Methods for the Treatment of Opioid Overdose,” includes claims covering combinations of nalmefene and Intravail® in a nasal formulation.

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose

SANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2022, after the financial markets close on Thursday, August 11, 2022.

Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

SANTA MONICA, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation and Human Capital Committee of the Company's Board of Directors has approved the grant of restricted stock units (“RSU”) covering an aggregate of 25,900 shares of common stock to seven hired employees, pursuant to the Company's 2022 Inducement Equity Incentive Plan (“Inducement Plan”). The RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar's production in support of OPNT003 Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar's production in support of OPNT003

Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene

SANTA MONICA, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced the filing of the first module of its New Drug Application (NDA) for OPNT003, nasal nalmefene, for the treatment of opioid overdose. The module was submitted pursuant to a rolling submission, as agreed with the U.S. Food and Drug Administration (FDA) during a pre-NDA meeting. As communicated previously, the Company expects to complete the submission of the NDA using the 505(b)(2) pathway in the second half of 2022.

Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast.  The meeting will be held online only and will begin at 09:00 AM PDT on June 14, 2022, as previously scheduled. The matters to be voted on at the 2022 Annual Meeting, remain unchanged.

Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor Relations Dr. Roger Crystal - Chief Executive Officer Dr. Phil Skolnick - Chief Scientific Officer David O'Toole - Chief Financial Officer Matt Ruth - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Leland LelGershell - Oppenheimer David Bautz - Zacks Operator Greetings, and welcome to Opiant Pharmaceuticals First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript

SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.

Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022

SANTA MONICA, Calif. , April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC.

Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overdose. This crossover study conducted in healthy volunteers compared 3 mg nasal nalmefene hydrochloride with 4 mg nasal naloxone.

Why Opiant Pharmaceuticals Shares Are Soaring Today

SANTA MONICA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a pharmacodynamic (“PD”) study for OPNT003, nasal nalmefene, (3mg nalmefene hydrochloride), an investigational treatment for opioid overdose.

Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript

SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - March 17. Management will also host investor 1x1 meetings.

Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference

SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates on Tuesday, March 15, 2022, after U.S. financial markets close.

Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022

SANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, an investigational treatment for opioid overdose. The crossover design study was conducted in 23 healthy subjects comparing the PK profile, safety, and tolerability of OPNT003 when given as a single 3mg dose in one nostril, as a single dose in each nostril, and as two doses in one nostril.

Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmaceuticals Inc's (NASDAQ: OPNT) OPNT003, nasal nalmefene, for opioid overdose.   The increase in funding is primarily directed toward the costs of Opiant's clinical studies to support its submission of OPNT003 to the FDA.

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.2 million to support OPNT003, nasal nalmefene, for opioid overdose. The increase in funding is primarily directed toward the costs of Opiant's clinical studies to support its submission of OPNT003 to the Food and Drug Administration (“FDA”).

Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD).  The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (WHO) drinking risk levels.

Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder

SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the first patient has been dosed in a Phase 2 clinical trial of OPNT002, nasal naltrexone, for the treatment of Alcohol Use Disorder (“AUD”). The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (“WHO”) drinking risk levels1.

News for Opiant Pharmaceuticals Stock (OPNT)